Latest Breaking News On - மைக்கேல் பணக்காரன் - Page 1 : comparemela.com

Share: BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (IND)-enabling data for NC762 at the American Association for Cancer Research (AACR) Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer. The research presented by our team reinforces our confidence that NC762, our third program, is a novel immunomedicine with unique anti-tumor properties. We believe it has the potential to provide benefit in multiple oncology indications, particularly in cancers where high B7-H4 expression has been observed, such as breast, ovarian and lung cancers, said Michael Richman, NextCure s president and chief executive officer. We look forward to advancing NC76

United statesMichael richmanEmily wong macdougallTimothy mayerExchange commissionAmerican association for cancer researchPhd nextcure incNextcure incAmerican associationCancer researchAnnual meetingFunctional characterizationTumor immune systemPrivate securities litigation reform actInquiries timothy mayerChief operating officer